** Shares of teleheath firm Hims & Hers Health HIMS.N fall 3.8% to $15.83
** Wall Street titan JPMorgan Chase JPM.N has cut its stake in HIMS from 8.1% to 1.7%, a regulatory filing showed as of February 27
** Hims has faced a wave of controversies in recent weeks after announcing and quickly withdrawing a $49 compounded version of Novo Nordisk’s NOVOb.CO weight‑loss drug Wegovy, following legal threats and regulatory scrutiny
** The company when reporting earnings said it would be facing a $65 million burden in the first quarter from changes in the shipping of weight-loss products, which must be personalized for each prescription based on U.S. law
** Including session's move, HIMS stock has halved YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))